Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07721025 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy

Study acronym: SUNRISE-FA 2
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoints added 1 → 9 primary endpoints
See other at-risk trials from Lexeo Therapeutics

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified
    • Secondary endpoints revised (15)
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy in participants with Friedreich ataxia (FA) cardiomyopathy (CM).
Trial Details
NCT Number NCT07721025
Lead Sponsor Lexeo Therapeutics
Conditions
(from sponsor)		 Friedreich Ataxia, Cardiomyopathy, Secondary
Related terms Cardiomyopathies, Cardiomyopathy, Hypertrophic, Friedreich Ataxia, Heart Diseases, Hypertrophy, Left Ventricular
Enrollment 26 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov